This site is intended for health professionals only
Wednesday 26 October 2016 Instagram
Share |

Heavy menstrual bleeding should not necessarily lead to hysterectomy

Heavy menstrual bleeding should not necessarily lead to hysterectomy

NICE recommends use of nonsurgical methods to treat heavy menstrual bleeding

A report by NICE has recommended the use of Mirena® (the levonorgestrel-releasing intrauterine system [IUS] from Schering Health Care) for firstline treatment of heavy menstrual bleeding (HMB) in women for whom hormonal treatment is appropriate.

The guidance marks a move from the practices of the early 1990s when, says the guideline, it was estimated that at least 60% of women presenting with HMB would have a hysterectomy – often as a firstline treatment.

Schering medical director, Dr Rebecca Curtis, commented: "This guidance is good news for clinicians and patients alike. It offers a clear evidence-based pathway for the management of HMB, which adversely affects the quality of life of many women.

"As well as its therapeutic use in this condition, the IUS also offers a reliable form of long-acting contraception (LARC), which lasts up to five years, as previously recommended by the NICE LARC guideline."

Leading GP and RCGP women's health spokesperson, Dr Sarah Jarvis, said: "The levonorgestrel-releasing IUS, as an extremely reliable and convenient form of contraception with a high satisfaction rate, is one which I regularly recommend to patients both for contraception and for the treatment of HMB.

"I welcome the NICE guidance, which confirms its place as a first-line treatment for the management of HMB in women for whom hormonal treatment is appropriate."

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?